Merck (NYSE:MRK) Insider Ownership

: 0.14 % (As of Today)

View and export this data going back to 1949. Start your Free Trial

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Merck's insider ownership is 0.14%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Merck's Institutional Ownership is 52.64%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Merck's Float Percentage Of Total Shares Outstanding is 99.94%.

Merck Insider Ownership Historical Data

The historical data trend for Merck's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Historical Data

The historical data trend for Merck can be seen below:

	2022-11-30	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2023-08-31
Insider Ownership	0.14	0.14	0.15	0.14	0.14	0.14	0.14	0.14	0.14	0.14

Merck Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Merck (NYSE:MRK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

MRK:Peru MRK:Mexico 6MKd:UK 0QAH:UK 6MK:Germany 6MK:Germany 6MK:Germany 6MK:Germany MRCK34:Brazil MRK:Austria MRK:Argentina

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Executives

Joseph Romanelli	officer: President, Human Health Int?l	126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Chirfi Guindo	officer: Chief Marketing Officer	C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr	director	370 WBASHA ST NORTH, ST PAUL MN 55102
Johannes Jacobus Oosthuizen	officer: SVP, U.S. Market	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Arpa Garay	officer: SVP Human Health Global Mktg.	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Cristal N Downing	officer: Chief Comm. & Public Afrs Ofcr	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Michael A Klobuchar	officer: EVP - Chief Strategy Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lisa Lecointe-cephas	officer: SVP Chief Ethics & Com Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield	officer: EVP & CFO	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Dean Y Li	officer: Executive VP & President, MRL	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams	officer: EVP,Chief Info&Digital Officer	MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Christine E Seidman	director	MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathy J Warden	director	2980 FAIRVIEW PARK DRIVE, FALLS CHURCH VA 22042